Andre Turenne, Matchpoint Therapeutics CEO (Jen Randall Photography)
October 14, 2022 06:30 AM EDTUpdated October 25, 01:44 PM
Financing
Startups

For­mer Voy­ager CEO An­dre Turenne makes a come­back with At­las-backed co­va­lent drug biotech 

Lei Lei Wu

News Reporter

Last May, An­dre Turenne re­signed from his CEO and pres­i­dent posts at Voy­ager to “pur­sue oth­er op­por­tu­ni­ties” af­ter the neu­ro­science biotech, once one half …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times